MediciNova (TSE:4875) Research & Development: 円991.33 Mil (TTM As of Mar. 2026)


TSE:4875 MediciNova Inc TSE:4875
28 GF Score
Price 円215.00
! 2 Warning Signs
View Full Analysis

What is MediciNova Research & Development?

MediciNova TSE:4875 28 Research & Development is 円991.33 Mil as of Mar. 2026. GuruFocus rates TSE:4875 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MediciNova's Research & Development for the three months ended in Mar. 2026 was 円200.42 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was 円991.33 Mil.

MediciNova  (TSE:4875) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MediciNova Research & Development Related Terms

MediciNova Research & Development Historical Data

* Premium members only.

The historical data trend for MediciNova's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MediciNova Research & Development Chart

MediciNova Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 971.91 1,233.66 814.65 1,106.69 1,115.57

MediciNova Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 274.27 316.27 234.07 240.58 200.42
TSE:4875
28GF Score
MediciNova Inc TSE:4875
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MediciNova Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円991.33 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円991.33 Mil mean?
MediciNova (TSE:4875) has a Research & Development of 円991.33 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MediciNova and its competitors.
Is MediciNova's Research & Development too high?
MediciNova's current Research & Development is 円991.33 Mil. Overall, MediciNova has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does MediciNova's Research & Development compare to ENTX and IMA?
MediciNova's Research & Development of 円991.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MediciNova and its competitors. MediciNova's current Research & Development is 円991.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediciNova stock overvalued right now?
MediciNova (TSE:4875) has a current Research & Development of 円991.33 Mil. The current Research & Development is 円991.33 Mil. MediciNova's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MediciNova (TSE:4875), the current Research & Development is 円991.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MediciNova Business Description

Other Exchanges MNOV:USA
Address 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
28GF Score

Get the complete analysis for TSE:4875

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円215.00
Price